Tag

Bloomberg Businessweek Archives - Carey Danis & Lowe

Vaginal Mesh Lawsuit News: Endo & American Medical Systems Settle Vaginal Mesh Lawsuits for $54.4 Million

By | Defective Medical Device litigation, Transvaginal Mesh, Uncategorized

transvaginal_mesh_mdl_2013_settlements_side_effects_court_filing_lawsuitsEndo Health Solutions Inc. and its subsidiary, American Medical Systems, agreed to a $54.4 million settlement of vaginal mesh lawsuits. Endo and American Medical Systems recently filed the settlement agreement with the U.S. Securities and Exchange Commission (SEC).

In a Bloomberg Businessweek article about the settlement, Endo did not disclose how many vaginal mesh lawsuits would be settled with the $54.4 million. The settlement will only involve a very small number of vaginal mesh lawsuits, and it will not apply to vaginal mesh lawsuits consolidated into the U.S. District Court for the Southern District of West Virginia.

Approximately 5,000 vaginal mesh lawsuits have been consolidated into a multidistrict litigation (MDL) in the West Virginia federal court. The first bellwether trial in the American Medical Systems MDL is scheduled for December 2013. The American Medical Systems MDL is In re: American Medical Systems, Inc., Pelvic Repair System Products Liability Litigation MDL No. 2325. The American Medical Systems MDL is being presided over by U.S. District Judge Joseph R. Goodwin.

Plaintiffs have filed vaginal mesh lawsuits against Endo and American Medical Systems alleging their vaginal mesh products eroded and caused severe pelvic pain.

Carey Danis & Lowe vaginal mesh lawyers are continuing to investigate vaginal mesh cases. Our vaginal mesh lawyers are also offering free legal evaluations to individuals who believe to have been injured by a vaginal mesh product manufactured by Endo and American Medical Systems or any other vaginal mesh product manufacturer, including CR Bard, Johnson & Johnson, Boston Scientific Corp., Coloplast Corp., or Cook Medical Inc.

 

For a free legal evaluation and assistance with filing a vaginal mesh lawsuit, contact Carey Danis & Lowe today by calling 800.721.2519 or submit a personal injury claim form.

Cooper v. Takeda Jury Presented with Plaintiff Closing Argument Linking Actos and Bladder Cancer

By | Actos, Pharmaceutical litigation, Uncategorized

takeda_actos_bladder_cancer_lawsuit_litigation_settlements_trial_filing_risk_cancerTakeda Pharmaceuticals, the Japanese pharmaceutical giant responsible for the development and marketing of the diabetes drug Actos, concealed the association between Actos and bladder cancer, a jury was recently told in an Actos trial.

ccording to a Bloomberg Businessweek report on the Actos trial being heard in Los Angeles, as early as 2004, Takeda knew about the associated between Actos and bladder cancer. Furthermore, with this awareness, the Japanese pharmaceutical company failed to inform the U.S. Food and Drug Administration (FDA), according to the plaintiffs lawyer in the case, Michael Miller.

Closing arguments in the Actos lawsuit were delivered from Miller on April 15, with the jury moving into deliberation on or after April 16 following closing statements from Takeda’s lawyers.

Due to Cooper’s ailing state, Takeda’s lawyers have pointed again and again to Cooper’s health being to blame for his bladder cancer, not Actos. It will be interesting to see if this argument holds any weight during jury deliberation.

The case is Cooper v. Takeda, and is being heard in a California Superior Court in Los Angeles by Judge Kenneth Freeman. As the plaintiff, Jack Cooper, is in poor health, his Actos lawsuit was given priority in going to trial. Once Cooper’s case is settled, Takeda still faces approximately 3,000 more Actos lawsuits, according to a Bloomberg Businessweek report.

The FDA approved Actos in 1999, and since then has ordered Takeda to continually update the drug’s label in order to provide adequate warnings about various health risks associated with Actos use. The current Actos drug label lists a warning about bladder cancer noting that in patients who have used Actos for longer periods, the risk of bladder cancer has increased considerably.

Carey Danis & Lowe Actos lawyers believe that the Cooper Actos case will be representative of and influence future Actos trials and lawsuits. With the evidence brought before the jury in the Cooper case about the dangers of taking Actos, our Actos lawyers believe that injured parties deserve justice and compensation, especially in cases where patients take a drug believing there to be minimal risks, but in reality, these risks have been concealed, resulting in serious harm and injury.

If you or a loved one has been injured by Actos, contact a Carey Danis & Lowe Actos lawyer by calling 800.721.2519 or by submitting a legal claim form.

Bayer Loses Yaz Patent in Federal Court of Appeals: Generic Yaz Versions Begin (Stealing) Marketshare

By | Pharmaceutical litigation, Uncategorized, Yaz/Yasmin

yaz_lawsuit_yasmin_lawsuit_ocella_lawsuit_settlements_litigation_mdl_lawsuit_settlement_amounts_gallbladder_removal_disease_surgeryBayer was recently dealt a setback in a Federal Court of Appeals in Washington. Their patent on Yaz, a contraceptive pill, was deemed to no longer be worthy of patent protection. Bayer’s patent on Yaz expires in June 2014.

As a result of this ruling, Actavis Inc. and Novartis AG can sell generic versions of the birth control pill. Though the ruling now gives other pharmaceutical companies the ability to legally compete against Bayer in the drospirenone contraceptive pill market, generic and inexpensive versions of Yaz-like drugs are driving Bayer’s profits significantly lower. In fact, Bayer stated that Yaz sales fell by 6.9 percent in the fourth quarter alone, according to Bloomberg Businessweek.

The Bayer Yaz patent decision was decided in the U.S. Court of Appeals for the Federal Circuit in Washington. The case is Bayer Healthcare Pharma v. Sandoz Inc. Bayer is currently seeking an appeal.

Though the drop in Yaz sales may be related to increasing competition from generic versions of drospirenone, Yaz has also been put in the negative spotlight for the contraceptive drug’s association with health risks, specifically blood clots, stroke, deep vein thrombosis, and in some cases, these severe Yaz side effects have proven to be fatal. According to a Bloomberg article, Bayer spent $1.57 billion in 2012 towards legal costs in Yaz and Yasmin lawsuits.

Yaz lawyers at Carey Danis & Lowe recognize that the loss of Bayer’s patent will introduce generic, inexpensive versions of drospirenone onto the market. With the firm link between Yaz and blood clots, these generic versions of Yaz have the potential to injure more women.

Carey Danis & Lowe is concerned about this drug’s ability to harm, and with this concern, our defective drug lawyers are closely working alongside our clients to bring them justice, compensation, and relief for injuries, suffering, and pain.

 

If you or someone you love has been injured by Yaz or Yasmin, contact a Carey Danis & Lowe Yaz and Yasmin lawyer. Our Yaz lawyers and Yasmin lawyers are currently offering a free legal evaluation about Yaz and Yasmin cases, and will provide assistance in filing a Yaz lawsuit or a Yasmin lawsuit.

Carey Danis & Lowe can be contacted by phone by calling 800.721.2519 or by submitting a legal claim form.